CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor
Makaleler > Tam Makale · 2019
Yazarlar: Banu Deveci, Belgin Sert Serdar, Pinar Karabacakoglu Kemik, Hatice Simsek Keskin, Nuri YILDIRIM, Necmettin ÖZDEMİR, Tugba Erkmen, Merat Koyuncuoglu, Mustafa Coşan TEREK, Ugur Saygili, Semra Kocturk
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2019, cilt 44, ss 438-451
Özet
Objective: Cancer Antigen 125 (CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) score are used for classification of ovarian masses (benign/malign) in preoperative stage. However, their discrimination capacity are considered insufficient, and greatly effected by histological subtype and menopausal status. This study aimed to investigate diagnostic performance of Human epididymis protein 4 (HE4), Y (tyrosine), K (lysine), and L (leucine)-40 (YKL-40), Mesothelin, Rho GDP dissociation inhibitor beta (LyGDI), CA125 or their combinations in discrimination of benign/malign ovarian diseases in preoperative stage.